retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Retatrutide, a (GLP1, GIP, glucagon), just released 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Research: Triple Agonist Mechanism
Description
The STEP3 trial involved 611 patients with obesity or overweight, semaglutide 2.4 mg treatment demonstrated an average weight loss of 10.3%, with 86.6% of participants achieving over 5% weight reduction (vs
When appetite is low, protein shakes and Greek yogurt provide easy options that most users tolerate well even during peak side effect periods
US9993430B2
However, this reduced side effect profile reflects reduced efficacy, not superior safety or outcomes
